Genmab (GMAB) Stock News

Genmab A/S advanced 4.4% to DKK2,482.00 on Tuesday, outpacing the OMX Nordic 40 Index which rose 0.9%. Volume was nearly three times the 50-day average.

Genmab shares jumped 8.3% after positive late-stage trial results for Epkinly in diffuse large B-cell lymphoma. The drug, developed with AbbVie, reduced risk of disease progression or death by 51% when added to standard treatment. Analysts say results exceeded expectations and could change front-line treatment.

Phase 3 EPCORE DLBCL-2 trial met primary endpoint; epcoritamab + R-CHOP reduced risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL patients with IPI 2-5. Safety consistent. Companies to engage regulators.

Genmab and AbbVie reported a 51% reduction in the risk of disease progression or death in a clinical trial. No further details were immediately available.

Genmab announced that its antibody-drug conjugate Rina-S demonstrated durable responses in a phase 2 trial for ovarian cancer. No further details were provided.